Scenario Please read this scenario prior to answering the Question You are serving as the
Lead Architect for an enterprise architecture project team within a leading medical device
manufacturer that specializes in miniature devices. The latest product under development is
a tiny wireless device that can be implanted in the brain and can deliver a precise electric
shock when the wearable Pain Control Unit (PCU) detects an increase in stress induced by

the onset of a migraine headache. This technology will be a breakthrough in the treatment
of this condition, and several competitors are striving to be the first to introduce a product
into the market. However, all of them must demonstrate the effectiveness and safety of their
products in a set of clinical trials that will satisfy the regulatory requirements of the countries
in the target markets. The Enterprise Architecture group within the company has been
engaged in an architecture development project to create a secure networked collaboration
system that will allow researchers at its product development laboratories worldwide to
share information about their independent clinical trials. The Enterprise Architecture group is
a mature organization that has been utilizing TOGAF for several years. They use the
TOGAF 9 ADM with extensions required to support current good manufacturing practices
and good laboratory practices in their target markets. Due to the highly sensitive nature of
the information that is managed, special care was taken to ensure that each architecture
domain included an examination of the security and privacy issues that are relevant for each
domain. A corresponding Security Architecture has been defined. The Executive Vice
President for Clinical Research is the sponsor of the Enterprise Architecture activity. She
has stated that the changes to the enterprise architecture for the new system will need to be
rolled out on a geographic basis that will minimize disruptions to ongoing clinical trials. The
work will need to be done in stages and rolled out in geographical regions. Refer to the
Scenario You have been asked to recommend the approach to identify the work packages
that will be included in the Transition Architecture(s). Based on TOGAF 9, which of the
following is the best answer?

A.
Use a Consolidated Gaps, Solutions and Dependencies Matrix as a planning tool. For
each gap classify whether the solution is either a new envelopment, purchased solution, or
based on an existing product. Group the similar solutions together to define the work
packages. Regroup the work packages into a set of Capability Increments to transition to
the Target Architecture taking into account the schedule for clinical trials.

B.
Group the Solution Building Blocks from a Consolidated Gaps, Solutions and
Dependencies Matrix into a set of work packages. Using the matrix as a planning tool,
regroup the work packages to account for dependencies. Sequence the work packages into
the Capability Increments needed to achieve the Target Architecture. Schedule the rollout
one region at a time. Document the progression of the enterprise architecture using a state
evolution table.

C.
Determine the set of Solution Building Blocks required by identifying which Solution
Building Blocks need to be developed and which need to be procured. Eliminate any
duplicate building blocks. Group the remaining Solution Building Blocks together to create
the work packages using a CRUD matrix. Rank the work packages in terms of cost and
select the most cost-effective options for inclusion in a series of Transition Architectures.
Schedule the roll out of the work packages to be sequential across the geographic regions.

D.
Create an Implementation Factor Assessment and Deduction Matrix and a Consolidated
Gaps, Solutions and Dependencies Matrix. For each gap, identify a proposed solution and
classify it as new development, purchased solution, or based on an existing product. Group
similar solutions together to form work packages. Identify dependencies between work
packages factoring in the clinical trial schedules. Regroup the packages into a set of
Capability Increments scheduled into a series of Transition Architectures.